Abstract
COVID-19 pandemic has changed the world dramatically since was first reported in Wuhan city, China [1]. Not only as a respiratory illness that could lead to fatal respiratory failure, but also some evidences suggest that it can propagate as a chronic disease associated with a variety of persistent post COVID-19 pathologies that affect patients’ life [2,3]. Pulmonary hypertension (PH) is one of the challenging diseases that may develop as a consequence of SARS-COV-2 infection in some COVID-19 survivors [4,5]. The vasopressor, proliferative, proinflammatory, and prothrombotic actions of endothelin [6] may be encountered in the COVID-19-induced PH pathology. And so, endothelin blockers may have an important role to restrict the development of serious PH outcomes with special precautions considering patients with significant hypoxemia.
【저자키워드】 Inflammation, thrombosis, fibrosis, pulmonary hypertension, Post COVID syndrome, Endothelin, 【초록키워드】 COVID-19, pathology, Respiratory failure, COVID-19 pandemic, Infection, Respiratory illness, outcome, pulmonary, hypertension, chronic disease, China, proinflammatory, Hypoxemia, Wuhan, Patient, disease, Precaution, Evidence, blocker, COVID-19 pathology, survivor, Affect, prothrombotic, develop, reported, variety, restrict, changed, proliferative, 【제목키워드】 pathology,